Fan Fangtian, Wu Hongyan, Liu Zhaoguo, Hou Xianbang, Chen Wenxin, Wang Aiyun, Lu Yin
Department of Pharmacy, Nanjing University of Chinese Medicine Hanlin College, Taizhou 225300, China.
College of Pharmacy, Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chine-se Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China; Department of Pharmacy, Yancheng Health Vocational and Technical College, Yancheng 224005, China.
Biomed Pharmacother. 2016 Dec;84:1858-1864. doi: 10.1016/j.biopha.2016.10.108. Epub 2016 Nov 25.
Surgical resection, providing a long-term survival of hepatocellular carcinoma (HCC) patients, is regarded as one of the standard curative treatments of HCC if the tumor is resectable. However, 50% patients develop early recurrence (ER) during the first two years after operation, which are more diffuse and rarely treatable with unsatisfactory long-term survival. Unfortunately, the underlying mechanisms of ER after curative resection and the molecular markers with predictive and prognostic significance have never been identified yet. Recent studies reveal that pyruvate kinase M2 (PKM2) levels were correlated with overall survival and disease-free survival in patients with HCC. The present study was aimed to investigate the correlation between the expression of PKM2 and ER. Our findings demonstrated that not the total PKM2 expression but the nuclear PKM2 expression as an independent risk factor for ER after curative resection, and could be a promising intervention target following curative resection for HCC patients.
手术切除可使肝细胞癌（HCC）患者获得长期生存，若肿瘤可切除，手术切除被视为HCC的标准治愈性治疗方法之一。然而，50%的患者在术后两年内出现早期复发（ER），复发更为弥漫，且很少能得到有效治疗，长期生存率不理想。遗憾的是，根治性切除术后早期复发的潜在机制以及具有预测和预后意义的分子标志物尚未明确。最近的研究表明，丙酮酸激酶M2（PKM2）水平与HCC患者的总生存期和无病生存期相关。本研究旨在探讨PKM2表达与早期复发之间的相关性。我们的研究结果表明，不是总PKM2表达，而是核PKM2表达是根治性切除术后早期复发的独立危险因素，并且可能是HCC患者根治性切除术后有前景的干预靶点。
